ReShape Lifesciences (RSLS) said Monday that the US Patent and Trademark Office awarded a notice of allowance for its proprietary diabetes neuromodulation technology, under patent application, titled high-frequency low duty cycle patterns for neural regulation.
The neuromodulation technology uses vagus nerve block technology platform, along with vagus nerve stimulation, to treat type 2 diabetes.
The technology regulates blood glucose through targeted vagal nerve modulation, specifically, blocking and stimulating signals to the liver and pancreas, the company's director of research Jonathan Waataja said.
Once issued, the patent will provide protection until Aug. 4, 2037.
Price: 0.46, Change: +0.15, Percent Change: +48.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.